Advances in Anticancer Agents in Medicinal Chemistry

Volume 2

by

Michelle Prudhomme

DOI: 10.2174/97816080549611130201
eISBN: 978-1-60805-496-1, 2013
ISBN: 978-1-60805-715-3
ISSN: 2214-4331

  
  




Advances in Anticancer Agents in Medicinal Chemistry is an exciting eBook series comprising a selection of updated articles previously...[view complete introduction]
PDF US $
- Single user / Non-Library usage: 119
- Multi user / Library usage: 476
Print-On-Demand (P.O.D): *143
Special Offer for Single user / Non-Library usage (PDF + P.O.D): *202

*(Excluding Mailing and Handling)
Purchase: Book Chapters
Download Flyers

Table of Contents

Foreword , Pp. i

William A. Denny

Download Free

Preface , Pp. ii-iii (2)

Michelle Prudhomme

Download Free

List of Contributors , Pp. iv-viii (5)

Michelle Prudhomme

Download Free

Marine Macrolides: Blue Biotechnology Against Cancer , Pp. 3-45 (43)

José G. Napolitano, Antonio H. Daranas, Manuel Norte and José J. Fernández

View Abstract Download Free

Recent Developments in Organometallic Supramolecular Complexes as Anticancer Drugs , Pp. 46-129 (84)

Cheng-He Zhou, Hui-Zhen Zhang, Sheng-Feng Cui, Jing-Song Lv, Cong-Yan Yan, Kun Wan, Yi-Yi Zhang, Shao-Lin Zhang, Gui-Xin Cai, Rong-Xia Geng and Guri L.V. Damu

View Abstract Purchase Chapter

Perspective Gold(III)-Dithiocarbamato Anticancer Therapeutics: Learning from the Past, Moving to the Future , Pp. 130-172 (43)

Luca Ronconi, Chiara Nardon, Giulia Boscutti and Dolores Fregona

View Abstract Purchase Chapter

Toward Anticancer Therapeutics Based on Glycidic Structures , Pp. 173-253 (81)

Luca Gabrielli, Alice Capitoli, Laura Russo, David Bini, Francesca Taraballi, Cristina Lupo and Laura Cipolla

View Abstract Purchase Chapter

Recent Highlights in the Development of Isatin-Based Anticancer Agents , Pp. 254-312 (59)

Kara L. Vine, Lidia Matesic, Julie M. Locke and Danielle Skropeta

View Abstract Purchase Chapter

Tripentones: A Promising Series of Potent Anti-Cancer Agents , Pp. 313-343 (31)

Christophe Rochais, Sylvain Rault and Patrick Dallemagne

View Abstract Purchase Chapter

Selective Estrogen Receptor Modulators as Treatments and Preventives of Breast Cancer , Pp. 344-396 (53)

Surojeet Sengupta, Jing Peng and Virgil C. Jordan

View Abstract Purchase Chapter

Targeting Leukemia Stem Cells with Novel Therapeutic Agents , Pp. 397-409 (13)

Yaoyu Chen, Cong Peng, Dongguang Li and Shaoguang Li

View Abstract Purchase Chapter

Targeting Migrating Cells in Glioblastoma , Pp. 410-443 (34)

Ranjith Babu, Chunhui Di, Austin K. Mattox, Steve Harward and Cory Adamson

View Abstract Purchase Chapter

Tyrosyl-DNA Phosphodiesterase 1 as a Target for Anticancer Therapy , Pp. 444-471 (28)

Thomas S. Dexheimer, Shar-yin N. Huang, Smitha Antony, Christophe Marchand and Yves Pommier

View Abstract Purchase Chapter

Index , Pp. 472-484 (13)

Michelle Prudhomme

Download Free

Foreword

This eBook in the Advances in Anticancer Agents in Medicinal Chemistry series continues the concept put together so well in the first volume of the series. By drawing on original articles published during 2008-2010 in Anticancer Agents in Medicinal Chemistry, and having them updated, the volume provides up-to-date reviews on a wide range of drug classes, including marine macrolides, metalbased complexes and glycoconjugate-based vaccines. Also discussed are biological targets through which to control leukemia stem cells, mitosis, metastasis, DNA repair and estrogen receptor modulation. Michelle Prudhomme, Editor-in-Chief of Anticancer Agents in Medicinal Chemistry, is to be commended for this new series, and for the selection of such a wide-ranging set of interesting reviews in Volume 2.

William A. Denny
Auckland Cancer Society Research Centre
University of Auckland
New Zealand


Preface

In Volume 2 of the eBook series Advances in Anticancer Agents in Medicinal Chemistry are gathered chapters on several classes of molecules exhibiting anticancer potentialities as well as some important targets for the development of novel anticancer drugs.

Marine macrolides are fascinating molecules with a large number of chiral centers. In the first chapter of Volume 2, Antonio H. Daranas, José J. Fernández and colleagues discuss the potential of marine macrolides in cancer therapy. Various families of marine macrolides and their biological targets are presented. Since the discovery of cisplatin, a huge interest has been paid to metal-based complexes as anticancer drugs. The second chapter by Chang-He Zhou et al. reviews the recent research and development of organometallic supramolecular complexes as anticancer agents. Whereas in the third chapter, Dolores Fregona and colleagues develop the potential of gold-based anticancer agents, in particular gold(III)-dithiocarbamato complexes which, due to their lower toxicity compared to the platinum drugs, could provide an interesting alternative.

In the search for anticancer vaccines, recent synthetic strategies towards glycoconjugates have been developed. These strategies and the development of glyconanoparticles are reviewed by Laura Cipolla and co-workers.

Isatin is an oxidised derivative of indole. Various substituted isatins exhibiting anticancer properties have been identified in plants and microorganisms. Isatin is a simple and excellent scaffold for the construction of new compounds of biological interest. Kara L. Vine, Lidia Matesic and colleagues summarize the recent structure-activity relationship studies on isatin-based compounds as anticancer agents.

The tripentone family represents a promising class of compounds, some of them exhibiting a potent cytotoxicity towards cancer cells. In their chapter, Patrick Dallemagne and collaborators review the different synthetic routes to tripentones and the emergence of the highly cytotoxic MR22388.

Endocrine therapy targeting to estrogen receptors (ER) and especially ER alpha has been very successful in the treatment and prevention of breast cancer. Virgil C. Jordan and co-workers provide an excellent update on the potential of selective estrogen receptor modulators.

Leukemia stem cells (LSCs) are defined as a small cell population required for the initiation and maintenance of leukemia. The chapter by Shaoguang Li and collaborators gives an overview on the development of new therapeutic strategies and drugs targeting LSCs.

Glioblastoma (GBM) is an aggressive disease associated with a poor prognostic due to a rapid migration of the GBM cells. In this review, Cory Adamson and colleagues describe various potential targets that may be exploited to inhibit the migration GBM cells.

The last chapter by Yves Pommier et al. is devoted to a DNA repair protein Tyrosyl-DNA phosphodiesterase 1 (Tdp1), an enzyme implicated in the repair of irreversible Top1-DNA covalent complexes. Rationale for the development of Tdp1 inhibitors for cancer therapy is discussed.

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand ICCF
CNRS UMR 6296 24 Avenue des Landais 63177 Aubiere Cedex
France

List of Contributors

Author(s):
Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand ICCF
France




Advertisement


Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science